Kidney disease after hematopoietic stem cell transplant-treatment standard

Area of Science:

• Nephrology
• Hematology
• Transplantation Medicine

Background:

• Hematopoietic stem cell transplant (HSCT) is crucial for treating various diseases.
• Kidney disease, including acute kidney injury (AKI) and chronic kidney disease (CKD), is a significant complication post-HSCT.
• Causes are multifactorial, including conditioning regimens, nephrotoxic drugs, graft-versus-host disease (GVHD), and transplant-associated thrombotic microangiopathy (TA-TMA).

Purpose of the Study:

• To review current diagnostic and therapeutic standards for kidney disease following HSCT.
• To highlight advancements in understanding pathophysiology and biomarkers.
• To discuss targeted therapies and future research directions.

Main Methods:

• Literature review of diagnostic and therapeutic strategies for kidney injury post-HSCT.
• Summary of current management protocols, including supportive care and immunomodulation.
• Discussion of novel biomarkers and targeted treatments.

Main Results:

• Kidney biopsy is often necessary for accurate diagnosis due to complex presentations.
• Targeted therapies like rituximab and eculizumab show promise for specific conditions.
• Renal replacement therapy and kidney transplantation are options for end-stage renal disease.

Conclusions:

• Early intervention and supportive care are critical for managing kidney complications post-HSCT.
• Advances in biomarkers and targeted therapies offer potential for improved outcomes.
• Further research is needed for noninvasive diagnostics and standardized protocols.